Application of microbial marker in diagnosis of uric acid abnormality related diseases

By detecting the mutation sites of microbial markers such as Prevotella_stercorea, Escherichia_coli, Bacteroides_eggerthii, combined with a variety of molecular biological technologies, the problem of insufficient sensitivity and specificity of diagnosis of uric acid abnormalities is solved, and efficient and non-invasive detection of uric acid abnormalities and predict.

CN119082330AActive Publication Date: 2024-12-06GENERAL HOSPITAL OF PLA
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
CN202411382997.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2024-01-23
Filing Date
2024-09-30
Publication Date
2024-12-06
Estimated Expiration
2044-09-30

AI Technical Summary

Technical Problem

The prior art is difficult to effectively diagnose and predict uric acid abnormalities, especially in the detection of microbial marker mutation levels, with insufficient sensitivity and specificity.

Method used

Specific mutation site detection of microbial markers such as Prevotella_stercorea, Escherichia_coli, Bacteroides_eggerthii, Bacteroides_xylanidens, Bacteroides_uniformis, Bacteroides_coprocola_CAG.162 and Lachnospiraceae_bacterium_8_1_57FAA was developed for uric acid abnormalities in combination with 16S sequencing, whole genome sequencing, quantitative polymerase chain reaction and other technologies. Diagnostic reagents and prediction systems for related diseases.

Benefits of technology

It improves the sensitivity and specificity of uric acid abnormality detection, provides a non-invasive, auxiliary diagnostic tool that can guide the adjustment of the intestinal microbial environment and reduces the possibility of uric acid abnormality.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119082330A_ABST
    Figure CN119082330A_ABST
Patent Text Reader

Abstract

The invention discloses an application of a microbial marker in diagnosis of diseases related to uric acid abnormality, and particularly relates to a microbial marker of Prevotella, Escherichia coli, Bacteroideshiggeri, Bacteroidellanies, Bacteroidellanies, Bacteroidellanies CAG.162, Bacnospiraceabacteria 8157FAA, and a preparation method of the microbial marker of the present invention, wherein the microbial marker of the present invention relates to the application of the microbial marker of the present invention in the diagnosis of diseases related to uric acid abnormality, the invention also discloses a product and a method for diagnosing uric acid abnormality related diseases, the product and the method comprise a reagent for detecting the mutation level of the microbial marker, and the product and the method provided by the invention have the advantages of noninvasive property, simplicity, strong specificity, high sensitivity, high safety and the like, and have wide market prospects.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biotechnology and relates to the application of microbial markers in diagnosing diseases related to abnormal uric acid, and specifically relates to the microorganisms Prevotella_stercorea, Escherichia_coli, Bacteroides_eggerthii, Bacteroides_xylanisolvens, Bacteroides_uniformis, Bacteroides_coprocola_CAG.162, and Lachnospiraceae_bacterium_8_1_57FAA. Background Art

[0002] Uric acid is the final product of purine metabolism in the human body. A normal adult produces about 700 mg of uric acid per day, of which about 500 mg is excreted through the kidneys and about 200 mg is excreted through the intestines to maintain uric acid balance in the body. Excessive production of uric acid or poor excretion of uric acid will lead to increased uric acid in the blood. In general, when the blood uric acid concentration is greater than 416 μmol / L, it can be clinically diagnosed as hyperuricemia. Once it is found that the uric acid level exceeds the standard, drinking low-fat food treatment is the first choice for controlling hyperuricemia and gout. Urate crystals in patients with hyperuricemia are deposited in the synovium, bursa, cartilage and other tissues of the joints, causing recurrent inflammatory diseases called gout, which manifest as gouty acute arthritis, chronic arthritis, tophi and joint deformities, gouty nephropathy, etc.

[0003] Intestinal microorganisms refer to the large number of microorganisms that exist in the intestines of animals. These microorganisms rely on the intestines of animals to survive and help the host complete a variety of physiological and biochemical functions. The intestine is not only an important place for human digestion and absorption, but also the largest immune organ, playing an extremely important role in maintaining normal immune defense functions. The human intestine provides a good habitat for microorganisms and has metabolic functions that the human body does not have. Summary of the invention

[0004] The present invention discloses the use of a reagent for detecting microbial markers in the preparation of a product for diagnosing abnormal uric acid-related diseases. The microbial markers include Prevotella_stercorea, Escherichia_coli, Bacteroides_eggerthii, Bacteroides_xylanisolvens, Bacteroides_uniformis, Bacteroides_coprocola_CAG.162, and Lachnospiraceae_bacterium_8_1_57FAA.

[0005] Further, the microbial marker is a combination of Prevotella_stercorea, Escherichia_coli, Bacteroides_eggerthii, Bacteroides_xylanisolvens, Bacteroides_uniformis, Bacteroides_coprocola_CAG.162, and Lachnospiraceae_bacterium_8_1_57FAA.

[0006] Furthermore, the microbial markers include a mutation at base position 4571 of the Prevotella_stercorea genome, a mutation at base position 1122339 of the Escherichia_coli genome, a mutation at base position 51594 of the Bacteroides_eggerthii genome, a mutation at base position 5120272 of the Bacteroides_xylanisolven genome, a mutation at base position 105620 of the Bacteroides_uniformis genome, a mutation at base position 246 of the Bacteroides_coprocola_CAG.162 genome, and a mutation at base position 77201 of the Lachnospiraceae_bacterium_8_1_57FAA genome, and the position of the mutation can be called a SNP site.

[0007] Furthermore, the microbial marker is a combination of a mutation at base position 4571 of the Prevotella_stercorea genome, a mutation at base position 1122339 of the Escherichia_coli genome, a mutation at base position 51594 of the Bacteroides_eggerthii genome, a mutation at base position 5120272 of the Bacteroides_xylanisolven genome, a mutation at base position 105620 of the Bacteroides_uniformis genome, a mutation at base position 246 of the Bacteroides_coprocola_CAG.162 genome, and a mutation at base position 77201 of the Lachnospiraceae_bacterium_8_1_57FAA genome.

[0008] In the present invention, the reference genome of the Prevotella_stercorea strain used is GenBank ID: QRNO01000027.1, and the reference genome link is: https: / / www.ncbi.nlm.nih.gov / nuccore / QRNO01000027.1, wherein the 4571st base in the reference genome is a T base, and when the T base at this site mutates to a C base, the risk of hyperuricemia is reduced.

[0009] In the present invention, the reference genome of the Escherichia coli strain used is GenBank ID: CP076470.1, and the reference genome link is: https: / / www.ncbi.nlm.nih.gov / nuccore / CP076470.1, wherein the 1122339th base in the reference genome is a G base, and when the G base at this site mutates to a C base, the risk of hyperuricemia increases.

[0010] In the present invention, the reference genome of the Bacteroides_eggerthii strain used is GenBank ID: CP072228.1, and the reference genome link is: https: / / www.ncbi.nlm.nih.gov / nuccore / CP072228.1, wherein the 51594th base in the reference genome is a T base, and the risk of hyperuricemia is reduced when the T base at this site mutates to a G or A base.

[0011] In the present invention, the reference genome of the Bacteroides_xylanisolvens strain used is GenBank ID: CP072216.1, and the reference genome link is: https: / / www.ncbi.nlm.nih.gov / nuccore / CP072216.1, wherein the 5120272nd base in the reference genome is a T base, and when the T base at this site mutates to a G base, the risk of hyperuricemia is reduced.

[0012] In the present invention, the reference genome of the Bacteroides_uniformis strain used is GenBank ID: CP054204.1, and the reference genome link is: https: / / www.ncbi.nlm.nih.gov / nuccore / CP054204.1, wherein the 105620th base in the reference genome is a C base, and when the C base at this site mutates to a T base, the risk of hyperuricemia increases.

[0013] In the present invention, the reference genome of the Bacteroides_coprocola_CAG.162 strain used is GenBank ID: FR881015.1, and the reference genome link is: https: / / www.ncbi.nlm.nih.gov / nuccore / FR881015.1, wherein the 246th base in the reference genome is a T base, and when the T base at this site mutates to a C base, the risk of hyperuricemia increases.

[0014] In the present invention, the reference genome of the Lachnospiraceae_bacterium_8_1_57FAA strain is GenBank ID: GL622453.1, and the reference genome link is: https: / / www.ncbi.nlm.nih.gov / nuccore / GL622453.1, wherein the 77201st base in the reference genome is a C base, and when the C base at this site mutates to a T base, the risk of hyperuricemia is reduced.

[0015] Furthermore, the product includes a reagent capable of detecting the microbial marker, a kit, a chip, a primer, a probe or a chromatography test paper containing the reagent.

[0016] Further, the reagents include specific primers, probes, antisense oligonucleotides, aptamers or antibodies for detecting Prevotella_stercorea, Escherichia_coli, Bacteroides_eggerthii, Bacteroides_xylanisolvens, Bacteroides_uniformis, Bacteroides_coprocola_CAG.162, and Lachnospiraceae_bacterium_8_1_57FAA.

[0017] Further, the reagent detects mutations at base 4571 of the Prevotella_stercorea genome (GenBank ID: QRNO01000027.1), mutations at base 1122339 of the Escherichia_coli genome (GenBank ID: CP076470.1), mutations at base 51594 of the Bacteroides_eggerthii genome (GenBank ID: CP072228.1), mutations at base 5120272 of the Bacteroides_xylanisolven genome (GenBank ID: CP072216.1), mutations at base 5120272 of the Bacteroides_uniformis genome (GenBank ID: CP072217.1), mutations at base 5120273 of the Bacteroides_xylanisolven genome (GenBank ID: CP072216.1), mutations at base 5120274 of the Bacteroides_uniformis genome (GenBank ID: CP072216.1), mutations at base 5120275 of the Bacteroides_xylanisolven genome (GenBank ID: CP072216.1), mutations at base 5120276 of the Bacteroides_xylanisolven genome (GenBank ID: CP072216.1), mutations at base 512027 ... Specific primers, probes, antisense oligonucleotides, aptamers or antibodies for mutations at base 105620 of the Bacteroides_coprocola_CAG.162 genome (GenBank ID: FR881015.1), at base 246 of the Bacteroides_coprocola_CAG.162 genome (GenBank ID: FR881015.1), and / or at base 77201 of the Lachnospiraceae_bacterium_8_1_57FAA genome (GenBank ID: GL622453.1).

[0018] In the present invention, the term "probe" refers to a molecule that can bind to a specific sequence or subsequence or other part of another molecule. Unless otherwise indicated, the term "probe" generally refers to a polynucleotide probe that can bind to another polynucleotide (often referred to as a "target polynucleotide") through complementary base pairing. Depending on the stringency of the hybridization conditions, the probe can bind to a target polynucleotide that lacks complete sequence complementarity with the probe. The probe can be directly or indirectly labeled, including primers. Hybridization methods include, but are not limited to: solution phase, solid phase, mixed phase or in situ hybridization assays.

[0019] Furthermore, the product includes determining the mutation of the microbial marker in the sample to determine whether the subject suffers from a disease related to abnormal uric acid or is at risk of suffering from a disease related to abnormal uric acid.

[0020] Furthermore, the sample includes blood, serum, and feces.

[0021] Furthermore, the method for detecting microbial markers in the sample includes any one or more of 16S sequencing, whole genome sequencing, quantitative polymerase chain reaction, PCR-pyrophosphate sequencing, fluorescence in situ hybridization, microarray, and / or PCR-ELISA detection.

[0022] Furthermore, the diseases related to abnormal uric acid include hyperuricemia, hypouricemia, gout, urinary tract stones, gouty nephropathy, and uric acid nephrolithiasis.

[0023] The present invention provides a method for determining the status of an individual using a microbial marker, wherein the microbial marker includes any of the microbial markers described above, and the method comprises:

[0024] 1) determining a mutation of the microbial marker in a sample of the individual;

[0025] 2) Comparing the mutation of the microbial marker determined in step 1) with its base in a control group, and determining the status of the individual based on the comparison results obtained, wherein the control group is composed of one or more groups of samples of individuals with the same status, including having a uric acid abnormality-related disease and / or not having a uric acid abnormality-related disease.

[0026] Further, the step 1) includes obtaining sequencing data of the nucleic acid sequence in the sample of the individual, wherein the sequencing data includes a plurality of read segments;

[0027] Aligning the read segment to the genome of the microbial marker to obtain an alignment result;

[0028] Based on the comparison results, the mutation level of the microbial marker is determined.

[0029] Furthermore, the control group in step 2) includes samples from multiple healthy individuals. When the mutations of the microbial markers determined in step 1) are the same as their bases in the control group, the individual is determined to be free of uric acid abnormality-related diseases.

[0030] Furthermore, the samples include blood, serum, and stool samples.

[0031] Furthermore, the diseases related to abnormal uric acid include hyperuricemia, hypouricemia, gout, urinary tract stones, gouty nephropathy, and uric acid nephrolithiasis.

[0032] In certain specific embodiments, the method of determining the status of an individual using a microbial marker includes obtaining sequencing data of nucleic acid sequences in a blood or serum sample of the individual, the sequencing data including multiple reads; assembling the reads to obtain a gene set, the gene set including multiple assembled fragments, the assembled fragments in the gene set being non-redundant sequences; determining the assembled fragments contained in the various microorganisms in the marker; based on the sequencing data, determining mutations of the various assembled fragments in the gene set, including determining mutation levels of the assembled fragments contained in the various microorganisms in the marker; and determining mutation levels of the various microorganisms based on the mutation levels of the determined assembled fragments.

[0033] The term "biomarker" should be understood in a broad sense, including any detectable biological indicator that can reflect an abnormal state, and may include gene markers, species markers (species markers / genus markers) and functional markers. Among them, the meaning of gene markers is not limited to existing genes that can be expressed as proteins with biological activity, but also includes any nucleic acid fragments, which can be DNA or RNA, modified DNA or RNA, or unmodified DNA or RNA. In this article, gene markers are sometimes also referred to as characteristic fragments. In particular, the biomarkers of the present invention are microbial markers.

[0034] The present invention provides a method for classifying multiple individuals using microbial markers, wherein the microbial markers include any of the microbial markers described above, and the method comprises:

[0035] Determining the status of each individual using the methods described above for determining the status of an individual using microbial markers;

[0036] The individuals are classified according to the obtained status of each individual.

[0037] Furthermore, the state of each individual is the state of the individual suffering from a disease related to abnormal uric acid or the risk of suffering from a disease related to abnormal uric acid.

[0038] Further, the state of the individual is determined by detecting any of the microbial markers described above, specifically:

[0039] When the 4571th base of the Prevotella_stercorea genome (GenBank ID: QRNO01000027.1) is T,

[0040] When the 1122339th base of the Escherichia_coli genome (GenBank ID: CP076470.1) is C,

[0041] When the 51594th base of the Bacteroides_eggerthii genome (GenBank ID: CP072228.1) is T,

[0042] When the 5120272nd base of the Bacteroides_xylanisolven genome (GenBank ID: CP072216.1) is T,

[0043] When the 105620th base of the Bacteroides_uniformis genome (GenBank ID: CP054204.1) is T,

[0044] When the 246th base of the Bacteroides_coprocola_CAG.162 genome (GenBank ID: FR881015.1) is C, and / or

[0045] When the 77201th base of the Lachnospiraceae_bacterium_8_1_57FAA genome (GenBank ID: GL622453.1) is C, the individual has a disease related to abnormal uric acid or has an increased risk of developing a disease related to abnormal uric acid;

[0046] When the 4571th base of the Prevotella_stercorea genome (GenBank ID: QRNO01000027.1) is C,

[0047] When the 1122339th base of the Escherichia coli genome (GenBank ID: CP076470.1) is G,

[0048] When the 51594th base of the Bacteroides_eggerthii genome (GenBank ID: CP072228.1) is G or A,

[0049] When the 5120272nd base of the Bacteroides_xylanisolven genome (GenBank ID: CP072216.1) is G,

[0050] When the 105620th base of the Bacteroides_uniformis genome (GenBank ID: CP054204.1) is C,

[0051] When the 246th base of the Bacteroides_coprocola_CAG.162 genome (GenBank ID: FR881015.1) is T, and / or

[0052] When the 77201st base of the Lachnospiraceae_bacterium_8_1_57FAA genome (GenBank ID: GL622453.1) is T, the individual suffers from a disease related to abnormal uric acid or has a reduced risk of suffering from a disease related to abnormal uric acid.

[0053] The present invention provides a product for diagnosing diseases related to abnormal uric acid, comprising a reagent for detecting the mutation levels of microbial markers Prevotella_stercorea, Escherichia_coli, Bacteroides_eggerthii, Bacteroides_xylanisolvens, Bacteroides_uniformis, Bacteroides_coprocola_CAG.162, and Lachnospiraceae_bacterium_8_1_57FAA.

[0054] Furthermore, the microbial marker includes any of the microbial markers described above.

[0055] Furthermore, the diseases related to abnormal uric acid include hyperuricemia, hypouricemia, gout, urinary tract stones, gouty nephropathy, and uric acid nephrolithiasis.

[0056] Furthermore, the reagent includes specific primers, probes, aptamers or antibodies for detecting the microbial markers.

[0057] "Primer" is an oligonucleotide that can initiate the synthesis of primer extension products in the presence of a suitable polymerizing agent when paired with a strand of DNA. Primers are preferably single-stranded to obtain maximum amplification efficiency, but may also be double-stranded. Primers must be long enough to initiate the synthesis of extension products in the presence of a polymerizing agent. The length of the primer depends on many factors, including application, temperature to be adopted, template reaction conditions, other reagents and primer sources. For example, depending on the complexity of the target sequence, oligonucleotide primers typically contain 15 to 35 or more nucleotide residues, but they may contain fewer nucleotide residues. Primers can be large polynucleotides, such as from about 200 nucleotide residues to several thousand bases or more. Primers can be selected to be "substantially complementary" to the sequence on the template to which they are designed to hybridize, and used as a site for synthesis initiation. "Substantially complementary" means that the primer complementarity is sufficient to hybridize with the target polynucleotide. In some embodiments, the primer does not contain mismatches with the template to which it is designed to hybridize, but this is not necessary. For example, non-complementary nucleotide residues can be connected to the 5' end of the primer, and the rest of the primer sequence is complementary to the template. Alternatively, non-complementary nucleotide residues or a stretch of non-complementary nucleotide residues may be interspersed within the primer, provided that the primer sequence has sufficient complementarity to the template sequence to which it is to hybridize and thereby form a template for the synthesis of primer extension products.

[0058] The term "diagnosis" or "aided diagnosis" refers to the identification or classification of a molecular or pathological state, disease or condition. For example, by molecular features (e.g., microbial communities, specific genes, proteins encoded by specific genes), the risk of dysuric acid or dysuric acid is identified.

[0059] As is well known to the skilled artisan, the step of associating a microbial marker mutation or content with a certain probability or risk can be implemented and realized in different ways. In a specific embodiment, the mutation level or content of the microbial marker is mathematically calculated and the calculated value is associated with the underlying diagnostic question. The markers can be combined by any suitable prior art mathematical method.

[0060] The present invention provides the use of microbial markers in constructing a computer model for diagnosing diseases related to abnormal uric acid, wherein the microbial markers include any of the microbial markers described above.

[0061] In a preferred embodiment of the application of the present invention, the input scalar of the computational model is the relative mutation level of the microbial markers Prevotella_stercorea, Escherichia_coli, Bacteroides_eggerthii, Bacteroides_xylanisolvens, Bacteroides_uniformis, Bacteroides_coprocola_CAG.162, and Lachnospiraceae_bacterium_8_1_57FAA. In a specific embodiment, the relative mutation level of the microbial marker is determined by one or more of metagenomic sequencing, 16S rRNA amplicon sequencing, droplet digital PCR, and qPCR quantitative detection.

[0062] The present invention uses the relative mutation level or content of the intestinal flora (i.e., the microbial marker of the present invention) as a predictive indicator. Therefore, it can be detected using the above-mentioned molecular biological methods. This diverse quantitative method can break the limitations of specific experimental conditions and experimental skills, so that some laboratories that do not have specific experimental equipment can also experiment with the data measurement and prediction of the present invention.

[0063] As used herein, the terms "comprises," "including," "having," "containing," or any other variation thereof, are used. For example, a composition, step, method, article, or apparatus that comprises the listed elements is not necessarily limited to only those elements but may include other elements not expressly listed or inherent to such composition, step, method, article, or apparatus.

[0064] The present invention provides a prediction system or device for abnormal uric acid-related diseases based on microbial markers, wherein the microbial markers include any of the microbial markers described above, and the prediction system or device includes:

[0065] Input unit: obtaining mutation level data of microbial markers obtained from subject samples;

[0066] Processing unit: analyzing and processing the mutation level data of the microbial markers input into the unit to obtain the prediction results of the subject;

[0067] Output unit: outputs the prediction result of the subject obtained by the analysis and processing of the processing unit;

[0068] Furthermore, the diseases related to abnormal uric acid include hyperuricemia, hypouricemia, gout, urinary tract stones, gouty nephropathy, and uric acid nephrolithiasis.

[0069] Furthermore, the samples include blood, serum, and stool samples.

[0070] In the present invention, the term "sample" includes cells, tissues, organs, body fluids (blood, lymph, etc.), digestive fluid, sputum, alveolar bronchial washings, urine, feces, etc. In a specific embodiment of the present invention, the sample is blood or serum.

[0071] In the present invention, "subject" includes animals that can suffer from or suffer from uric acid abnormalities, and examples of subjects include mammals, such as humans, non-human primates, dogs, cows, horses, pigs, sheep, goats, cats, mice, rabbits, rats, and transgenic non-human animals. In a specific embodiment of the present invention, the subject is a human.

[0072] Compared with the prior art, the present invention has the following beneficial effects:

[0073] The present invention provides microbial markers associated with abnormal uric acid, which have the potential to be used as markers for detecting abnormal uric acid and can be used for non-invasive auxiliary diagnosis of abnormal uric acid. They have good specificity, high sensitivity, and high cost-effectiveness, and can guide the adjustment of the microbial environment of the intestinal flora and reduce the possibility of abnormal uric acid. BRIEF DESCRIPTION OF THE DRAWINGS

[0074] Figure 1 This is the ROC curve of the test set using microbial markers to diagnose abnormal uric acid;

[0075] Figure 2 This is the ROC curve of the validation set using microbial markers for the diagnosis of abnormal uric acid;

[0076] Figure 3This is a schematic diagram of the flow chart of a prediction system or device for uric acid abnormality-related diseases based on microbial markers. DETAILED DESCRIPTION

[0077] The present invention is further described below in conjunction with specific embodiments, which are only used to explain the present invention and are not to be construed as limiting the present invention. It will be appreciated by those skilled in the art that various changes, modifications, substitutions and variations may be made to these embodiments without departing from the principles and purposes of the present invention, and that the scope of the present invention is defined by the claims and their equivalents. The experimental methods for which specific conditions are not specified in the following examples are usually tested under conventional conditions or under conditions recommended by the manufacturer.

[0078] As a preferred embodiment, the present invention comprises the following steps:

[0079] (1) Sample collection and processing: Collect relevant samples, use a kit to extract DNA, and obtain nucleic acid samples;

[0080] (2) Library construction and sequencing: DNA library construction and sequencing are performed using high-throughput sequencing to obtain the nucleic acid sequences of the intestinal microorganisms contained in the sample;

[0081] (3) Determine the specific intestinal microbial nucleic acid sequences associated with uric acid abnormalities through bioinformatics analysis methods.

[0082] AUC is the area under the estimated curve. The larger the AUC, the higher the diagnostic ability. For each species, a diagnostic critical value is determined so that the sum of the diagnostic sensitivity and specificity is the highest under this critical value. The detailed method for determining the critical value is as follows: sort the relative mutation levels of the species from small to large, and then sequentially select a value as the candidate critical value, calculate the sensitivity and specificity under this candidate critical value, and take the candidate critical value with the largest sum of sensitivity and specificity as the final optimal critical value.

[0083] Sensitivity is called the true positive rate, which is the probability that an actual patient is diagnosed as a patient by the indicator, that is, the probability that the patient is diagnosed as positive. Specificity is called the true negative rate, which refers to the probability that an actual non-diseased person is diagnosed as a non-patient by the indicator, that is, the probability that a non-patient is diagnosed as negative.

[0084] The terms used herein have the meanings commonly understood by those of ordinary skill in the art to which the present invention relates. Terms such as "a", "an", and "the" refer not only to singular entities, but also to general categories that may be used to describe specific embodiments. The terms herein are used to describe specific embodiments of the present invention, but their use does not limit the present invention unless indicated in the claims.

[0085] In the present invention, sequencing can be selected based on the selected sequencing platform, but is not limited to semiconductor sequencing technology platforms such as PGM, synthetic sequencing technology platforms such as Illumina's HISeq and Miseq sequencing platforms, and single-molecule real-time sequencing platforms such as PaCBio sequencing platforms. The sequencing method can be single-end sequencing or double-end sequencing, and the data obtained from the machine are the fragments read out, called read segments.

[0086] In the present invention, the so-called assembly can be performed using known sequence assembly methods or software, such as SOAPdenovo, velvet, etc.

[0087] Example 1 Screening and testing of intestinal flora associated with abnormal uric acid

[0088] 1. Research subjects and sample collection

[0089] A total of 258 samples were collected, including blood, serum and stool samples from 129 patients with abnormal uric acid and 129 healthy people.

[0090] 2. Experimental methods

[0091] 1) Blood, serum, and stool sample collection and DNA extraction

[0092] After collecting blood, serum and feces samples from the above-mentioned population, DNA was extracted using a kit to obtain extracted DNA samples.

[0093] 2) Metagenomic high-throughput sequencing and analysis

[0094] The microorganisms Prevotella_stercorea (Genome GenBank ID: QRNO01000027.1), Escherichia_coli (Genome GenBank ID: CP076470.1), Bacteroides_eggerthii (Genome GenBank ID: CP072228.1), Bacteroides_xylanisolvens (Genome GenBank ID: CP072216.1), Bacteroides_uniformis (Genome GenBank ID: CP054204.1), Bacteroides_coprocola_CAG.162 (Genome GenBank ID: FR881015.1), Lachnospiraceae_bacterium_8_1_57FAA (Genome GenBank ID: CP076470.1) were downloaded from the NCBI database. ID: GL622453.1) were used as the reference genomes of 7 microbial species. First, the sequences obtained from the original sequencing were quality controlled. The sequenced sequences after quality control were compared with the 7 genomes using BWA software to obtain the sequence of each genome. SAMTools software (parameter: "-vmO zV indels) and VCF tools software (parameters: 1 / d=10 / a=4 / Q=15 / q=10 / .) were used to find SNP sites and screen out high-quality SNP sites. In order to reduce the false positive results, VarScan2 software (parameters: "--min-coverage 10--min-reads24--min-var-freq 0.2--p-value 0.05.) was also used to find and screen SNPs. The SNP results finally used for downstream analysis took the intersection of the screening results of the two software.

[0095] 3) Diagnostic efficacy analysis

[0096] The R package "pROC" was used to draw the receiver operating curve (ROC) and analyze the AUC value, sensitivity, and specificity of the microbial markers in the test set that showed significant differences in mutation levels between healthy subjects and subjects with abnormal uric acid, in order to determine their diagnostic efficacy for diseases related to abnormal uric acid.

[0097] Among them, the mutation of the microbial marker is used for evaluation and analysis, and the point corresponding to the maximum Youden index is selected as its cutoff value, that is, the optimal division threshold is determined by the point with the largest Youden index.

[0098] 3. Experimental results

[0099] The BLINK software and FarmCPU software in GAPIT software were used to perform genome-wide association analysis on the SNPs in the bacterial genome and the uric acid phenotype. The results showed that the mutation levels of Prevotella_stercorea (genome GenBank ID: QRNO01000027.1), Escherichia_coli (genome GenBank ID: CP076470.1), Bacteroides_eggerthii (genome GenBank ID: CP072228.1), Bacteroides_xylanisolvens (genome GenBank ID: CP072216.1), Bacteroides_uniformis (genome GenBank ID: CP054204.1), Bacteroides_coprocola_CAG.162 (genome GenBank ID: FR881015.1), and Lachnospiraceae_bacterium_8_1_57FAA (genome GenBank ID: GL622453.1) strains were significantly correlated with uric acid levels.

[0100] The results of species difference analysis showed a mutation at base 4571 of the Prevotella_stercorea genome (Genome GenBank ID: QRNO01000027.1), a mutation at base 1122339 of the Escherichia_coli genome (Genome GenBank ID: CP076470.1), a mutation at base 51594 of the Bacteroides_eggerthii genome (Genome GenBank ID: CP072228.1), a mutation at base 5120272 of the Bacteroides_xylanisolven genome (Genome GenBank ID: CP072216.1), a mutation at base 105620 of the Bacteroides_uniformis genome (Genome GenBank ID: CP054204.1), and a mutation at base 11627 of the Bacteroides_coprocola_CAG.162 genome (Genome GenBank ID: CP076470.1). The mutation levels of the 246th base of the Lachnospiraceae_bacterium_8_1_57FAA genome (GenBank ID: GL622453.1) and the 77201st base of the Lachnospiraceae_bacterium_8_1_57FAA genome (GenBank ID: GL622453.1) showed significant differences, as shown in Table 1.

[0101] Table 1

[0102]

[0103]

[0104] The results showed that there were significant differences in the mutation levels of the seven microbial markers between the hyperuricemia population and the normal population. The OR values ​​showed that the mutation detection sites of the seven microbial markers were all influencing factors of hyperuricemia. The mutations at base 4571 of the Prevotella_stercorea genome (GenBank ID: QRNO01000027.1), base 51594 of the Bacteroides_eggerthii genome (GenBank ID: CP072228.1), base 5120272 of the Bacteroides_xylanisolven genome (GenBank ID: CP072216.1), and base 77201 of the Lachnospiraceae_bacterium_8_1_57FAA genome (GenBank ID: GL622453.1) were protective factors; Mutations in base 1,122,339 of the Bacteroides_uniformis genome (GenBank ID: CP054204.1), and base 246 of the Bacteroides_coprocola_CAG.162 genome (GenBank ID: FR881015.1) are risk factors.

[0105] Using microbial markers as detection variables, draw ROC curves and calculate their AUC values. The results are as follows: Figure 1 As shown, the AUC value was 0.8295, indicating that the combination of microbial markers as a detection variable has high specificity and sensitivity.

[0106] Example 2 Verification of the ability of microbial markers to diagnose diseases related to abnormal uric acid

[0107] 1. Research subjects and sample collection

[0108] Blood, serum and stool samples were collected from 50 sample groups, including 25 patients with abnormal uric acid and 25 healthy people.

[0109] 2. Experimental methods

[0110] 1) Blood, serum, and stool sample collection and DNA extraction

[0111] After collecting blood, serum and feces samples from the above-mentioned population, DNA was extracted using a kit to obtain extracted DNA samples.

[0112] 2) Metagenomic high-throughput sequencing and analysis

[0113] The microorganisms Prevotella_stercorea (Genome GenBank ID: QRNO01000027.1), Escherichia_coli (Genome GenBank ID: CP076470.1), Bacteroides_eggerthii (Genome GenBank ID: CP072228.1), Bacteroides_xylanisolvens (Genome GenBank ID: CP072216.1), Bacteroides_uniformis (Genome GenBank ID: CP054204.1), Bacteroides_coprocola_CAG.162 (Genome GenBank ID: FR881015.1), Lachnospiraceae_bacterium_8_1_57FAA (Genome GenBank ID: CP076470.1) were downloaded from the NCBI database. ID: GL622453.1) were used as the reference genomes of 7 microbial species. First, the sequences obtained from the original sequencing were quality controlled. The sequenced sequences after quality control were compared with the 7 genomes using BWA software to obtain the sequence of each genome. SAMTools software (parameter: "-vmO zV indels) and VCF tools software (parameters: 1 / d=10 / a=4 / Q=15 / q=10 / .) were used to find SNP sites and screen out high-quality SNP sites. In order to reduce the false positive results, VarScan2 software (parameters: "--min-coverage 10--min-reads24--min-var-freq 0.2--p-value 0.05.) was also used to find and screen SNPs. The SNP results finally used for downstream analysis took the intersection of the screening results of the two software.

[0114] 3) Diagnostic efficacy analysis

[0115] The R package "pROC" was used to draw the receiver operating curve (ROC) and analyze the AUC value, sensitivity, and specificity of the microbial markers in the test set that showed significant differences in mutation levels between healthy subjects and subjects with abnormal uric acid, in order to determine their diagnostic efficacy for diseases related to abnormal uric acid.

[0116] Among them, the mutation of the microbial marker is used for evaluation and analysis, and the point corresponding to the maximum Youden index is selected as its cutoff value, that is, the optimal division threshold is determined by the point with the largest Youden index.

[0117] 3. Experimental results

[0118] ROC curve analysis of microbial markers in diagnosing diseases related to abnormal uric acid

[0119] The mutation combination of microbial markers was used as the detection variable to draw the ROC curve and calculate its AUC value. The results are as follows Figure 2 As shown, the AUC value was 0.7613, indicating that the mutation combination of microbial markers can be used as a microbial marker for diagnosing diseases related to abnormal uric acid.

Claims

1. Use of a reagent for detecting microbial markers in the preparation of a product for diagnosing diseases related to abnormal uric acid, characterized in that: The microbial markers include Prevotella_stercorea, Escherichia_coli, Bacteroides_eggerthii, Bacteroides_xylanisolvens, Bacteroides_uniformis, Bacteroides_coprocola_CAG.162, and Lachnospiraceae_bacterium_8_1_57FAA; Preferably, the microbial marker is a combination of Prevotella_stercorea, Escherichia_coli, Bacteroides_eggerthii, Bacteroides_xylanisolvens, Bacteroides_uniformis, Bacteroides_coprocola_CAG.162, and Lachnospiraceae_bacterium_8_1_57FAA; Preferably, the microbial markers include a mutation at base 4571 of the Prevotella_stercorea genome, a mutation at base 1122339 of the Escherichia_coli genome, a mutation at base 51594 of the Bacteroides_eggerthii genome, a mutation at base 5120272 of the Bacteroides_xylanisolven genome, a mutation at base 105620 of the Bacteroides_uniformis genome, a mutation at base 246 of the Bacteroides_coprocola_CAG.162 genome, and a mutation at base 77201 of the Lachnospiraceae_bacterium_8_1_57FAA genome, and the position of the mutation can be referred to as a SNP site; Preferably, the microbial marker is a combination of a mutation at base position 4571 of the Prevotella_stercorea genome, a mutation at base position 1122339 of the Escherichia_coli genome, a mutation at base position 51594 of the Bacteroides_eggerthii genome, a mutation at base position 5120272 of the Bacteroides_xylanisolven genome, a mutation at base position 105620 of the Bacteroides_uniformis genome, a mutation at base position 246 of the Bacteroides_coprocola_CAG.162 genome, and a mutation at base position 77201 of the Lachnospiraceae_bacterium_8_1_57FAA genome.

2. The use according to claim 1, characterized in that: The product includes a reagent capable of detecting the microbial marker, a kit, a chip, a primer, a probe or a chromatography test paper containing the reagent; Preferably, the reagents include specific primers, probes, antisense oligonucleotides, aptamers or antibodies for detecting Prevotella_stercorea, Escherichia_coli, Bacteroides_eggerthii, Bacteroides_xylanisolvens, Bacteroides_uniformis, Bacteroides_coprocola_CAG.162, Lachnospiraceae_bacterium_8_1_57FAA; Preferably, the reagents include specific primers, probes, antisense oligonucleotides, aptamers or antibodies for detecting mutations at base position 4571 of the Prevotella_stercorea genome, mutations at base position 1122339 of the Escherichia_coli genome, mutations at base position 51594 of the Bacteroides_eggerthii genome, mutations at base position 5120272 of the Bacteroides_xylanisolven genome, mutations at base position 105620 of the Bacteroides_uniformis genome, mutations at base position 246 of the Bacteroides_coprocola_CAG.162 genome, and mutations at base position 77201 of the Lachnospiraceae_bacterium_8_1_57FAA genome.

3. The use according to claim 1, characterized in that: The product comprises determining the mutation level of the microbial marker in the sample to determine whether the subject suffers from a disease associated with abnormal uric acid or is at risk of suffering from a disease associated with abnormal uric acid; Preferably, the sample includes blood, serum, or feces.

4. The use according to claim 3, characterized in that: The diseases related to abnormal uric acid include hyperuricemia, hypouricemia, gout, urinary tract stones, gouty nephropathy, and uric acid nephrolithiasis.

5. A method for determining the status of an individual using microbial markers, characterized in that: The microbial marker comprises the microbial marker according to any one of claims 1 to 3, and the method comprises: 1) determining a mutation of the microbial marker in a sample of the individual; 2) comparing the mutation of the microbial marker determined in step 1) with the mutation in the control group, and determining the status of the individual based on the comparison results, wherein the control group is composed of one or more groups of samples of individuals with the same status, including having a disease related to abnormal uric acid and / or not having a disease related to abnormal uric acid.

6. The method according to claim 5, characterized in that The step 1) comprises obtaining sequencing data of a nucleic acid sequence in a sample of the individual, wherein the sequencing data comprises a plurality of read segments; Aligning the read segment to the genome of the microbial marker to obtain an alignment result; Determining the mutation level of the microbial marker based on the comparison result; Preferably, the control group in step 2) includes samples from multiple healthy individuals, and when the mutations of the microbial markers determined in step 1) are the same as the bases in the control group, the individual is determined to be free of uric acid abnormality-related diseases; Preferably, the sample includes blood, serum, or stool sample; Preferably, the diseases related to abnormal uric acid include hyperuricemia, hypouricemia, gout, urinary tract stones, gouty nephropathy, and uric acid nephrolithiasis.

7. A method for classifying multiple individuals using microbial markers, characterized in that: The microbial marker comprises the microbial marker according to any one of claims 1 to 3, and the method comprises: Determining the status of each individual using the method of claim 5 or 6; classifying each individual according to the obtained status of the individual; Preferably, the state of each individual is a state in which the individual suffers from a disease associated with abnormal uric acid or is at risk of suffering from a disease associated with abnormal uric acid; Preferably, the state of the individual is determined by detecting the microbial markers according to any one of claims 1 to 3, specifically: When the 4571th base of the Prevotella_stercorea genome is T, When the 1122339th base of the Escherichia coli genome is C, When the 51594th base of the Bacteroides_eggerthii genome is T, When the 5120272nd base of the Bacteroides_xylanisolven genome is T, When the 105620th base of the Bacteroides_uniformis genome is T, When the 246th base of the Bacteroides_coprocola_CAG.162 genome is C, and / or When the 77201st base of the Lachnospiraceae_bacterium_8_1_57FAA genome is C, the individual suffers from a disease related to abnormal uric acid or has an increased risk of suffering from a disease related to abnormal uric acid; When the 4571th base of the Prevotella_stercorea genome is C, When the 1122339th base of the Escherichia coli genome is G, When the 51594th base of the Bacteroides_eggerthii genome is G or A, When the 5120272nd base of the Bacteroides_xylanisolven genome is G, When the 105620th base of the Bacteroides_uniformis genome is C, When the 246th base of the Bacteroides_coprocola_CAG.162 genome is T, and / or When the 77201st base of the Lachnospiraceae_bacterium_8_1_57FAA genome is T, the individual suffers from a uric acid abnormality-related disease or has a reduced risk of suffering from a uric acid abnormality-related disease.

8. A product for diagnosing diseases related to abnormal uric acid, characterized in that: The product includes reagents for detecting mutation levels of microbial markers; Preferably, the microbial marker comprises the microbial marker according to any one of claims 1 to 3; Preferably, the diseases related to abnormal uric acid include hyperuricemia, hypouricemia, gout, urinary tract stones, gouty nephropathy, and uric acid nephrolithiasis; Preferably, the reagent comprises a specific primer, a probe, an aptamer or an antibody for detecting the microbial marker.

9. The use of microbial markers in constructing a computer model for diagnosing diseases related to abnormal uric acid, characterized in that: The microbial marker comprises the microbial marker according to any one of claims 1 to 3.

10. A prediction system or device for uric acid abnormality-related diseases based on microbial markers, characterized in that: The microbial marker comprises the microbial marker according to any one of claims 1 to 3, and the prediction system or device comprises: Input unit: obtaining mutation level data of microbial markers obtained from subject samples; Processing unit: analyzing and processing the mutation level data of the microbial markers input into the unit to obtain the prediction results of the subject; Output unit: outputs the prediction result of the subject obtained by the analysis and processing of the processing unit; Preferably, the diseases related to abnormal uric acid include hyperuricemia, hypouricemia, gout, urinary tract stones, gouty nephropathy, and uric acid nephrolithiasis; Preferably, the sample comprises a blood, serum or stool sample.

Citation Information

Patent Citations

  • Molecular marker for diagnosing diabetic nephropathy, and product and application thereof

    CN113481293A

  • Application of biomarkers in diagnosis of diabetic nephropathy

    CN113584158A

  • Acute altitude stress microbial marker and application thereof

    CN114839369A

  • Application of USP24 biomarker in diagnosis of diabetic nephropathy

    CN117305440A

  • Method and kit for assessing risk of gout and hyperuricemia

    US20100035255A1